Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
NCT05023655 · Prisma Health-Upstate · PHASE2 · terminated · last registry update 2026-03-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Ipsen has discontinued all active tazemetostat clinical trials and expanded access programs due to the emergence of a clinically unfavorable benefit risk profile for tazemetostat in combination with lenalidomide and rituximab.” | – | Registry record, Prisma Health-Upstate |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EZH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-11-10Also stopped (terminated): National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-10-28Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02875548)
- 2026-10-28Also stopped (terminated): Epizyme, Inc., Tazemetostat (NCT02875548)
- 2026-09-01Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Tazemetostat Hydrobromide (NCT04557956)
- 2026-04-17Also stopped (terminated): University of Alabama at Birmingham, Tazemetostat (NCT05983965)
- 2026-04-16Also stopped (terminated): Epizyme, Inc., Tazemetostat (NCT04241835)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-04-02Also stopped (terminated): Weill Medical College of Cornell University, Venetoclax + Tazemetostat (NCT05618366)
- 2026-04-01Also stopped (withdrawn): Eric Jacobsen, MD, Tazemetostat + Doxorubicin (NCT06692452)
- 2026-03-10Results posted on the registry: Epizyme, Inc., Tazemetostat + Abiraterone/prednisone (NCT04179864)
- 2026-03-10Also stopped (terminated): Epizyme, Inc., Tazemetostat + Abiraterone/prednisone (NCT04179864)
- 2026-02-04Results posted on the registry: University of Florida, Tazemetostat (NCT04917042)
- 2026-01-30Also stopped (withdrawn): Epizyme, Inc., Tazverik (Tazemetostat) (NCT06068881)
- 2026-01-21Also stopped (suspended): City of Hope Medical Center, Epcoritamab + Tazemetostat (NCT06575686)
- 2026-01-07Also stopped (terminated): Epizyme, Inc., Tazemetostat + Doxorubicin HCl (NCT04204941)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision